全文获取类型
收费全文 | 142822篇 |
免费 | 10249篇 |
国内免费 | 466篇 |
专业分类
耳鼻咽喉 | 1886篇 |
儿科学 | 3951篇 |
妇产科学 | 2574篇 |
基础医学 | 18750篇 |
口腔科学 | 2723篇 |
临床医学 | 14693篇 |
内科学 | 29920篇 |
皮肤病学 | 2118篇 |
神经病学 | 13409篇 |
特种医学 | 4989篇 |
外国民族医学 | 7篇 |
外科学 | 20307篇 |
综合类 | 2378篇 |
现状与发展 | 1篇 |
一般理论 | 192篇 |
预防医学 | 13093篇 |
眼科学 | 3163篇 |
药学 | 10185篇 |
3篇 | |
中国医学 | 177篇 |
肿瘤学 | 9018篇 |
出版年
2023年 | 527篇 |
2022年 | 914篇 |
2021年 | 2330篇 |
2020年 | 1372篇 |
2019年 | 2266篇 |
2018年 | 2596篇 |
2017年 | 1983篇 |
2016年 | 2179篇 |
2015年 | 2692篇 |
2014年 | 3832篇 |
2013年 | 5901篇 |
2012年 | 8546篇 |
2011年 | 9145篇 |
2010年 | 5134篇 |
2009年 | 4891篇 |
2008年 | 8666篇 |
2007年 | 9252篇 |
2006年 | 9095篇 |
2005年 | 9382篇 |
2004年 | 8858篇 |
2003年 | 8616篇 |
2002年 | 8212篇 |
2001年 | 1768篇 |
2000年 | 1563篇 |
1999年 | 1749篇 |
1998年 | 1930篇 |
1997年 | 1604篇 |
1996年 | 1372篇 |
1995年 | 1348篇 |
1994年 | 1122篇 |
1993年 | 1128篇 |
1992年 | 1239篇 |
1991年 | 1187篇 |
1990年 | 1120篇 |
1989年 | 1031篇 |
1988年 | 962篇 |
1987年 | 950篇 |
1986年 | 951篇 |
1985年 | 1071篇 |
1984年 | 1136篇 |
1983年 | 1093篇 |
1982年 | 1353篇 |
1981年 | 1206篇 |
1980年 | 1098篇 |
1979年 | 768篇 |
1978年 | 797篇 |
1977年 | 745篇 |
1976年 | 613篇 |
1975年 | 582篇 |
1974年 | 544篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
4.
5.
6.
7.
8.
9.
Osric A. Forrest Daniel M. Chopyk Yael Gernez Milton R. Brown Carol K. Conrad Richard B. Moss Vin Tangpricha Limin Peng Rabindra Tirouvanziam 《Journal of cystic fibrosis》2019,18(1):64-70
Background
Resistin is an immunometabolic mediator that is elevated in several inflammatory disorders. A ligand for Toll-like receptor 4, resistin modulates the recruitment and activation of myeloid cells, notably neutrophils. Neutrophils are major drivers of cystic fibrosis (CF) lung disease, in part due to the release of human neutrophil elastase- and myeloperoxidase-rich primary granules, leading to tissue damage. Here we assessed the relationship of resistin to CF lung disease.Methods
Resistin levels were measured in plasma and sputum from three retrospective CF cohorts spanning a wide range of disease. We also assessed the ability of neutrophils to secrete resistin upon activation in vitro. Finally, we constructed a multivariate model assessing the relationship between resistin levels and lung function.Results
Plasma resistin levels were only marginally higher in CF than in healthy control subjects. By contrast, sputum resistin levels were very high in CF, reaching 50–100 fold higher levels than in plasma. Among CF patients, higher plasma resistin levels were associated with allergic bronchopulmonary aspergillosis, and higher sputum resistin levels were associated with CF-related diabetes. Mechanistically, in vitro release of neutrophil primary granules was concomitant with resistin secretion. Overall, sputum resistin levels were negatively correlated with CF lung function, independently of other variables (age, sex, and genotype).Conclusions
Our data establish relationships between resistin levels in the plasma and sputum of CF patients that correlate with disease status, and identify resistin as a novel mechanistic link between neutrophilic inflammation and lung disease in CF. 相似文献10.
Caroline E. Sloan Judy Zhong Dinushika Mohottige Rasheeda Hall Clarissa J. Diamantidis Leight E. Boulware Virginia Wang 《Seminars in dialysis》2020,33(6):440-448
Caring for patients with end-stage kidney disease (ESKD) in the United States is challenging, due in part to the complex epidemiology of the disease's progression as well as the ways in which care is delivered. As CKD progresses toward ESKD, the number of comorbidities increases and care involves multiple healthcare providers from multiple subspecialties. This occurs in the context of a fragmented US healthcare delivery system that is traditionally siloed by provider specialty, organization, as well as systems of payment and administration. This article describes the role of care fragmentation in the delivery of optimal ESKD care and identifies research gaps in the evidence across the continuum of care. We then consider the impact of care fragmentation on ESKD care from the patient and health system perspectives and explore opportunities for system-level interventions aimed at improving care for patients with ESKD. 相似文献